Erdi Bazhen decoction for cancer-related fatigue due to qi and blood deficiency in prostate cancer patients receiving androgen deprivation therapy: an exploratory randomized, double-blind, placebo-controlled pilot clinical trial protocol
Open Access
- 13 October 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1970591
Abstract
Background: Prostate cancer is the most common male genitourinary malignancy in China. Long-term androgen deprivation therapy (ADT) causes severe cancer-related fatigue (CRF), which impairs patients’ physical function and quality of life. Currently, there is a lack of safe, long-term specific pharmacological agents for this condition in Western medicine. From the perspective of traditional Chinese medicine (TCM), qi and blood deficiency is the core pathogenesis underlying the occurrence and progression of CRF. Erdi Bazhen Decoction (EBD) has shown favorable clinical effects on fatigue after ADT in routine practice, but high-quality clinical evidence remains scarce, and key parameters for large-scale confirmatory trials remain undetermined. This exploratory pilot trial aims to investigate the preliminary efficacy and safety of EBD granules for CRF in prostate cancer patients receiving ADT, and to estimate critical trial parameters including effect size, recruitment rate, adherence and dropout rate to inform the design of a future large-scale confirmatory RCT. Methods: This single-center, prospective, randomized, double-blind, placebo-controlled parallel pilot trial will enroll 50 eligible patients from a single hospital. Participants will be randomly assigned to two groups at a 1:1 ratio. Both groups will receive routine supportive care for 4 weeks. The intervention group will receive EBD granules, and the control group will receive matched placebo granules. The primary exploratory efficacy endpoint is the change in total score of the revised Piper Fatigue Scale (PFS-R) from baseline to week 4. Secondary outcomes include quality of life, physical performance and TCM syndrome scores; hemoglobin and C-reactive protein levels will be assessed as exploratory biomarkers. Trial feasibility parameters such as recruitment rate, medication adherence and dropout rate will also be descriptively analyzed to inform future trial design. Safety indicators and adverse events will be fully recorded. Variable block randomization without stratification and full double-blinding will be implemented. The primary analysis will be conducted in the intention-to-treat population; a per-protocol analysis will be performed as a sensitivity analysis. All efficacy estimates are exploratory. This protocol was designed in accordance with the SPIRIT 2025 statement; trial results will be reported in accordance with the CONSORT 2025 statement. Conclusion: This standardized pilot controlled trial will provide preliminary clinical evidence and essential methodological parameters for EBD in relieving ADT-related fatigue. The results may offer preliminary support for a safe TCM regimen to improve patients’ fatigue, physical status and quality of life, and lay a methodological foundation for integrated Chinese and Western medicine management of prostate cancer-related fatigue. As an exploratory pilot study, the single-center design, small sample size and short intervention period limit the generalizability of confirmatory conclusions. Further large-scale, multi-center, long-term confirmatory trials are needed to verify the long-term effects and population applicability of EBD. Clinical Trial Registration: https://itmctr.ccebtcm.org.cn/ , identifier [ITMCTR2026001527].Keywords
This publication has 43 references indexed in Scilit:
- Endocrine therapy‐induced cancer‐related fatigue in hormone‐dependent malignancies: Mechanisms, impact, and management strategiesPrecision Medical Sciences, 2026
- Effect of contact needle technique on cancer-related fatigue in palliative care patients: a randomized controlled trialSupportive Care in Cancer, 2026
- An integrated research strategy based on “compound exogenous chemical substances-endogenous metabolites in disease”: To explore the scientific basis of Modified Bazhen Yimu Gao in the treatment of primary dysmenorrheaJournal of Ethnopharmacology, 2025
- The effectiveness of digital psychosocial interventions on psychological distress, depression, anxiety, and health-related quality of life in patients with gynaecological cancer: a systematic review and meta-analysisSupportive Care in Cancer, 2024
- Management of Fatigue in Patients with Advanced CancerCurrent Treatment Options in Oncology, 2023
- Epidemiology and Prevention of Prostate CancerEuropean Urology Oncology, 2021
- Effect of Chinese medicine treatment based on pattern identification on cellular immunophenotype of myelodysplastic syndromeChinese Journal of Integrative Medicine, 2016
- Treatment with modified Bazhen Decoction (八珍汤) for a patient with autoimmune hemolytic anemia: A case report of a ten-month periodChinese Journal of Integrative Medicine, 2014
- The Piper Fatigue Scale-12 (PFS-12): psychometric findings and item reduction in a cohort of breast cancer survivorsBreast Cancer Research and Treatment, 2012
- Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for designStatistics in Medicine, 1992